We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
Read MoreHide Full Article
Key Takeaways
HOLX's Breast Health segment fell 6.2% in Q2, continuing a decline led by weaker capital equipment sales.
Despite softness, Hologic's service revenues rose 12%, driven by a large global gantry install base.
HOLX eyes a growth rebound in Q4 and plans a 2026 launch of its FDA-cleared Envision mammography platform.
Women’s health medical device maker, Hologic (HOLX - Free Report) , is struggling with continued softness in its core Breast Health segment. Sales fell 6.2% in the fiscal 2025 second quarter due to weaker sales of capital equipment. This follows a 2.1% drop in the three months ended December 2024. So, is the downward trend temporary, or does it cloud the segment’s long-term growth prospects?
Gantry placements are expected to remain soft throughout 2025, following two years of elevated mammography shipments post chip shortage. This has led to Hologic’s annual forecast of a low-single-digit decline for Breast Health, with a mid-single-digit organic decline. Still, management’s assumption of growth returning in the fourth quarter signals optimism for the next fiscal year and beyond.
The company holds nearly 80% of the U.S. market with its industry-leading 3D Genius mammography machine. Recurring service revenues, tied to the global installed base of nearly 15,000 gantries, remain the segment’s largest contributor and grew 12% year over year in the second quarter. Hologic’s focus on bolstering the processes, capabilities and leadership in this business helps drive stronger margins. Further, the highly anticipated Envision platform, featuring the first FDA-approved mammography innovation of its kind, is set to make its commercial debut in fiscal 2026.
The 2024 acquisition of Endomagnetics has significantly enhanced Hologic’s Interventional Breast portfolio. The company is upbeat in its momentum through the rest of the year and has recently begun a direct sales approach of Endomag products via its North American salesforce, aiming to capture the expanding wireless localization market.
HOLX Peer Comparison
One of Hologic’s key breast health rivals, GE Healthcare (GEHC - Free Report) , delivered record double-digit order growth in the first quarter of 2025 due to higher U.S. customer investments in imaging products, particularly for cardiology and oncology. GEHC’s organic imaging revenues increased 5% year over year. GE Healthcare’s new Invenia Automated Breast Ultrasound Premium is the first FDA-approved breast ultrasound supplemental screening technology for detecting cancer in dense breasts.
Meanwhile, Becton, Dickinson and Company (BDX - Free Report) , or BD, is a prominent market player in breast biopsy devices sold through its Peripheral Intervention business unit. While the broader Interventional segment dropped 2.2% in the fiscal 2025 second quarter, BDX expects stronger growth in the second half, fueled by PureWick and Phasix. BD’s new Phasix ST Umbilical Hernia Patch should also contribute.
The Zacks Rundown for HOLX
Year to date, Hologic shares have dropped 12.6%, steeper than the industry’s decline of 9.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, HOLX trades at a forward 12-month earnings multiple of 14.02X compared to the industry average of 28.64X. It carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HOLX’s earnings for both fiscal 2025 and 2026 has been revised downward over the past 90 days.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
Key Takeaways
Women’s health medical device maker, Hologic (HOLX - Free Report) , is struggling with continued softness in its core Breast Health segment. Sales fell 6.2% in the fiscal 2025 second quarter due to weaker sales of capital equipment. This follows a 2.1% drop in the three months ended December 2024. So, is the downward trend temporary, or does it cloud the segment’s long-term growth prospects?
Gantry placements are expected to remain soft throughout 2025, following two years of elevated mammography shipments post chip shortage. This has led to Hologic’s annual forecast of a low-single-digit decline for Breast Health, with a mid-single-digit organic decline. Still, management’s assumption of growth returning in the fourth quarter signals optimism for the next fiscal year and beyond.
The company holds nearly 80% of the U.S. market with its industry-leading 3D Genius mammography machine. Recurring service revenues, tied to the global installed base of nearly 15,000 gantries, remain the segment’s largest contributor and grew 12% year over year in the second quarter. Hologic’s focus on bolstering the processes, capabilities and leadership in this business helps drive stronger margins. Further, the highly anticipated Envision platform, featuring the first FDA-approved mammography innovation of its kind, is set to make its commercial debut in fiscal 2026.
The 2024 acquisition of Endomagnetics has significantly enhanced Hologic’s Interventional Breast portfolio. The company is upbeat in its momentum through the rest of the year and has recently begun a direct sales approach of Endomag products via its North American salesforce, aiming to capture the expanding wireless localization market.
HOLX Peer Comparison
One of Hologic’s key breast health rivals, GE Healthcare (GEHC - Free Report) , delivered record double-digit order growth in the first quarter of 2025 due to higher U.S. customer investments in imaging products, particularly for cardiology and oncology. GEHC’s organic imaging revenues increased 5% year over year. GE Healthcare’s new Invenia Automated Breast Ultrasound Premium is the first FDA-approved breast ultrasound supplemental screening technology for detecting cancer in dense breasts.
Meanwhile, Becton, Dickinson and Company (BDX - Free Report) , or BD, is a prominent market player in breast biopsy devices sold through its Peripheral Intervention business unit. While the broader Interventional segment dropped 2.2% in the fiscal 2025 second quarter, BDX expects stronger growth in the second half, fueled by PureWick and Phasix. BD’s new Phasix ST Umbilical Hernia Patch should also contribute.
The Zacks Rundown for HOLX
Year to date, Hologic shares have dropped 12.6%, steeper than the industry’s decline of 9.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, HOLX trades at a forward 12-month earnings multiple of 14.02X compared to the industry average of 28.64X. It carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HOLX’s earnings for both fiscal 2025 and 2026 has been revised downward over the past 90 days.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here